Multimodal image-guided surgery of HER2-positive breast cancer using [111In]In-DTPA-trastuzumab-IRDye800CW in an orthotopic breast tumor model

被引：0
|
作者：
Marion M. Deken
Desirée L. Bos
Willemieke S. F. J. Tummers
Taryn L. March
Cornelis J. H. van de Velde
Mark Rijpkema
Alexander L. Vahrmeijer
机构：
[1] Leiden University Medical Center,Department of Surgery
[2] Radboud University Medical Center,Department of Radiology and Nuclear Medicine
[3] Leiden University Medical Center,Department of Clinical Pharmacy and Toxicology
来源：
EJNMMI Research | / 9卷
关键词：
Multimodal imaging; HER2-positive breast cancer; [; In]In-DTPA-trastuzumab-IRDye800CW; Fluorescence; Image-guided surgery;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer
    Zhang, Li
    Chen, Yimeng
    Lv, Yao
    Jiao, Shunchang
    Zhao, Weihong
    ONCOLOGIST, 2022, 27 (04): : 245 - 250
  • [32] Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report
    Chen, Yuanping
    Liu, Chao
    Wen, Xinglin
    Wang, Chen
    He, Jing
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2024, 16 : 1277 - 1283
  • [33] Targeting the tumor microenvironment by CXCR4 inhibition to abrogate trastuzumab resistance in HER2-positive breast cancer
    Liu, S.
    Xie, S. M.
    Yang-Kolodji, G.
    Tripathy, D.
    CANCER RESEARCH, 2019, 79 (04)
  • [34] Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer
    Chen, Weirong
    Zhang, Juncheng
    Huang, Lijian
    Chen, Lin
    Zhou, Yanling
    Tang, Dongjiang
    Xie, Yingming
    Wang, Hong
    Huang, Chuoji
    CLINICAL BREAST CANCER, 2019, 19 (01) : E239 - E246
  • [35] Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer
    Kashiwagi, Shinichiro
    Asano, Yuka
    Goto, Wataru
    Takada, Koji
    Takahashi, Katsuyuki
    Hatano, Takaharu
    Takashima, Tsutomu
    Tomita, Shuhei
    Motomura, Hisashi
    Ohsawa, Masahiko
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2017, 37 (10) : 5623 - 5630
  • [36] Preclinical translational bridge studies supporting advancement of 111In-Bn-DTPA-NLS-trastuzumab to Phase I clinical trial in patients with HER2-positive breast cancer
    Chan, C.
    Cai, Z.
    Done, S.
    Reilly, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S690 - S691
  • [37] Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
    Sasagu Kurozumi
    Kenichi Inoue
    Hiroshi Matsumoto
    Takaaki Fujii
    Jun Horiguchi
    Tetsunari Oyama
    Masafumi Kurosumi
    Ken Shirabe
    Scientific Reports, 9
  • [38] Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
    Kurozumi, Sasagu
    Inoue, Kenichi
    Matsumoto, Hiroshi
    Fujii, Takaaki
    Horiguchi, Jun
    Oyama, Tetsunari
    Kurosumi, Masafumi
    Shirabe, Ken
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [39] Development of microRNA-based prediction model of trastuzumab treatment response for HER2-positive breast cancer using FFPE specimens
    Sato, F.
    Ueno, T.
    Myomoto, A.
    Takizawa, S.
    Masuda, N.
    Aogi, K.
    Kondo, N.
    Mikami, Y.
    Saji, S.
    Toi, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S118 - S119
  • [40] Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model
    Yamashita-Kashima, Yoriko
    Shu, Sei
    Yorozu, Keigo
    Moriya, Yoichiro
    Harada, Naoki
    ONCOLOGY LETTERS, 2017, 14 (04) : 4197 - 4205
12345